Multiple Perspectives on Security

Security Journal

Subscribe to Security Journal: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Security Journal: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn


Security Journal Authors: Elizabeth White, Yeshim Deniz, Pat Romanski, Maria C. Horton, Liz McMillan

News Feed Item

St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership

- Focusing on Development of Treatments For Women with Endometriosis -

PHOENIX and BRITISH COLUMBIA, Canada, Sept. 19 /PRNewswire-FirstCall/ -- St. Joseph's Hospital and Medical Center, part of Catholic Healthcare West, one of the largest healthcare systems in the West with 42 hospitals in Arizona, California and Nevada and InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces a collaborative partnership focusing on the development of treatments for women with endometriosis.

"I am pleased to announce this new partnership between St. Joseph's Hospital and InNexus to explore, develop and commercialize new therapeutic solutions for women," said Jeff Morhet, Chairman and CEO of InNexus Biotechnology, "We've already identified our first project, aimed at providing new treatments to attack the problem of endometriosis, a painful condition that can lead to other conditions, such as infertility."

"We're excited to join InNexus in pursuing new treatments to help women with endometriosis," says Linda Hunt, President of St. Joseph's. "We hope this is the first of many collaborations that will ultimately help patients in need."

Scientific activities of the partnership will be conducted in facilities of both St. Joseph's Hospital and Medical Center and InNexus' GLP (Good Lab Practice) certified drug development laboratories with funding provided by research grants, the partners and strategic collaborators. Additional details were not disclosed.

About Endometriosis

According to the National Institutes of Health, endometriosis occurs when tissues that usually grow inside the uterus instead grow on the outside. These tissues often grow on the surfaces of organs in the pelvis or abdomen, where they are not supposed to grow.

Endometriosis is one of the most common gynecological diseases, affecting more than 5.5 million women in North America. An estimated 2 to 10 percent of women of reproductive age have endometriosis. Additional information can be found at http://www.nichd.nih.gov/health/topics/endometriosis.cfm.

About St. Joseph's Hospital and Medical Center

Located in the heart of Phoenix, Arizona, St. Joseph's Hospital and Medical Center is a 743-bed, not-for-profit hospital that is recognized for outstanding patient care, medical education and research. The hospital is part of Catholic Healthcare West (CHW), one of the largest healthcare systems in the West with 42 hospitals in Arizona, California and Nevada. You can find out more about St. Joseph's Hospital and Medical Center at http://www.stjosephs-phx.org.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

SOURCE InNexus Biotechnology Inc.; St. Joseph's Hospital and Medical Center

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.